Purdue Pharma expected to dissolve after reaching tentative opioid settlement

Purdue Pharma.
(Image credit: Drew Angerer/Getty Images)

Members of the Sackler family, who own Purdue Pharma, have reportedly tentatively reached a settlement with lawyers representing thousands of local governments, states, and tribes across the United States in lawsuits over the drug manufacturer's alleged role in creating the country's opioid crisis. The deal is similar to one the company proposed in August and will eventually result in Purdue, which is expected to soon file for bankruptcy, paying up to $12 billion.

Two people involved in the negotiations told The New York Times that the settlement requires Purdue's dissolution as a company and the formation of a new company that the Sacklers will not control, but that will continue to sell OxyContin — Purdue's signature opioid. The proceeds, however, will reportedly go to a public beneficiary company that will pay the plaintiffs. Purdue will also reportedly donate "rescue" drugs for addiction treatment and overdose reversal. The settlement reportedly does not include a statement of wrongdoing from Purdue or the Sackler family.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.